UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy

Journal of allergy and clinical immunology, 2017-07, Vol.140 (1), p.162-169.e2

2017

Volltextzugriff (PDF)

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-01, Vol.7 (1), p.156-164.e1

2019

Volltextzugriff (PDF)

Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2014-09, Vol.2 (5), p.544-552.e2

2014

Volltextzugriff (PDF)

Pharmacoeconomics of Biologic Therapy

Immunology and allergy clinics of North America, 2017-05, Vol.37 (2), p.413-430

2017

Volltextzugriff (PDF)

Particle size of inhaled corticosteroids: Does it matter?

Journal of allergy and clinical immunology, 2009-12, Vol.124 (6), p.S88-S93

2009

Volltextzugriff (PDF)

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Annals of allergy, asthma, & immunology, 2017-12, Vol.119 (6), p.524-532.e2

2017

Volltextzugriff (PDF)

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Annals of allergy, asthma, & immunology, 2018-05, Vol.120 (5), p.549-550

2018

Volltextzugriff (PDF)

Higher Immunoglobulin E (IgE) Levels Are Associated with Greater Emergency Care and Other Healthcare Utilization Among Asthma Patients in a Real-World Data Setting

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB9-AB9

2016

Volltextzugriff (PDF)

Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio

Journal of managed care & specialty pharmacy, 2017-11, Vol.23 (11), p.1117

2017

Volltextzugriff (PDF)

Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB9-AB9

2017

Volltextzugriff (PDF)

Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB8-AB8

2017

Volltextzugriff (PDF)

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2018-01, Vol.6 (1), p.169-176.e2

2018

Volltextzugriff (PDF)

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis

ClinicoEconomics and outcomes research, 2016-01, Vol.8, p.641-648

2016

Volltextzugriff (PDF)

The reality of adherence to rhinitis treatment: identifying and overcoming the barriers

Allergy and asthma proceedings, 2011-07, Vol.32 (4), p.265

2011

Volltextzugriff (PDF)

Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB14-AB14

2016

Volltextzugriff (PDF)

Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma

Allergy and asthma proceedings, 2011-05, Vol.32 (3), p.185

2011

Volltextzugriff (PDF)

What the asthma end points we know and love do and do not tell us

Journal of allergy and clinical immunology, 2005-04, Vol.115 (4), p.S539-S545

Luskin, Allan T.

2005

Volltextzugriff (PDF)

Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper

Allergy and asthma proceedings, 2011-03, Vol.32 (2), p.168

2011

Volltextzugriff (PDF)

Association Between Severity of Asthma Exacerbations and Asthma-Related Quality of Life in Patients With Severe or Difficult-to-Treat Asthm

Chest, 2011-10, Vol.140 (4), p.863A-863B

2011

Volltextzugriff (PDF)

“Real-world” effectiveness of daily controller medicine in children with mild persistent asthma

Annals of allergy, asthma, & immunology, 2003-05, Vol.90 (5), p.543-549

2003

Volltextzugriff (PDF)

Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters

Journal of allergy and clinical immunology, 2011-06, Vol.127 (6), p.1640-1641.e1

2011

Volltextzugriff (PDF)

The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

Annals of allergy, asthma, & immunology, 2004-12, Vol.93 (6), p.538-545

2004

Volltextzugriff (PDF)

Treatment Response To Omalizumab And Reduced Asthma Exacerbations And Asthma-Related Healthcare Resource Use From The Real-World PROSPERO Study

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB21

2020

Volltextzugriff (PDF)

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

Clinical therapeutics, 2001-09, Vol.23 (9), p.1589-1600

2001

Volltextzugriff (PDF)

Asthma quality-of-care measures using administrative data: identifying the optimal denominator

Annals of allergy, asthma, & immunology, 2009-02, Vol.102 (2), p.98-102

2009

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(62)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(39)
Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Allergy
(28)
Immunology
(22)
Asthma - Drug Therapy
(20)
Female
(18)
Adult
(17)
Male
(17)
Adolescent
(16)
Asthma
(16)
Middle Aged
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Anti-Asthmatic Agents - Therapeutic Use
(14)
Child
(13)
Allergy And Immunology
(12)
Patients
(9)
Treatment Outcome
(9)
Aged
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma

Pharmacoeconomics of Biologic Therapy

Particle size of inhaled corticosteroids: Does it matter?

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Higher Immunoglobulin E (IgE) Levels Are Associated with Greater Emergency Care and Other Healthcare Utilization Among Asthma Patients in a Real-World Data Setting

Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio

Clinically Significant Improvements in Asthma Patient-Reported Outcomes: Results from the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study

Decreased Asthma Exacerbations and Hospitalizations in PROSPERO (Prospective Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab)

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life

Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis

The reality of adherence to rhinitis treatment: identifying and overcoming the barriers

Biomarkers Associated with Response in Patients Initiating Omalizumab: Baseline Levels Among Patients in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO) Study

Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma

What the asthma end points we know and love do and do not tell us

Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paper

Association Between Severity of Asthma Exacerbations and Asthma-Related Quality of Life in Patients With Severe or Difficult-to-Treat Asthm

“Real-world” effectiveness of daily controller medicine in children with mild persistent asthma

Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters

The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes

Treatment Response To Omalizumab And Reduced Asthma Exacerbations And Asthma-Related Healthcare Resource Use From The Real-World PROSPERO Study

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

Asthma quality-of-care measures using administrative data: identifying the optimal denominator

Suchergebnisse filtern